Vimarsana
Biggest News Aggregation in the World

Page 3 - Monitoring Recommendations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Monitoring Recommendations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Monitoring Recommendations Today - Breaking & Trending Today

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen - Vimarsana News

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

Share this article TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ -- Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regener...

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19 - Vimarsana News

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

REGN) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. "The peer-reviewed NEJM publication of our first set of clinical data in recently infected COVID-19 patients showed that casirivimab and imdevimab effectively reduced viral load and the need for medically-attended visits, with the greatest benefit in patients who had not yet mounted their own effective immune response or had high viral load at baseli...